Agilent Completes Acquisition of Proscia
- Agilent completed its previously announced acquisition of digital pathology software provider Proscia for $240 million in cash at closing.
- The deal includes up to $30 million in additional payments tied to future performance milestones.
- Proscia joins the Life Sciences and Diagnostics Markets Group, adding a recurring-revenue software business to the pathology portfolio.
- The acquisition combines pathology instrumentation and reagents with Proscia's platform to support AI-enabled diagnostics and drug discovery.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agilent Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261104915315) on November 04, 2026, and is solely responsible for the information contained therein.